ReviewInternational journal of molecular sciences2026
Gut Microbiota Dysbiosis in Depression: Pathological Correlations, Molecular Pathways, and Therapeutic Interventions.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Gut Modulators Alter BDNF/Cortisol Axis in Severe Obesity: Additional Secondary Outcomes from a Triple-Blind Randomized Trial.Life (Basel, Switzerland) · 2026Article
- Efavirenz-Altered Gut-Microbiota,International journal of molecular sciences · 2026Article
- Early Gut Microbiota and Neurodevelopmental Trajectories: Implications for Pediatric Neuropsychiatric Vulnerability-A Narrative Review.Nutrients · 2026Review
- Butyrate Is Associated with the Antidepressant Effects ofInternational journal of molecular sciences · 2026Article
- Gut microbial biomarkers for major depressive disorder: a cross-sectional study.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Major depressive disorder (MDD) ranks as a primary contributor to global ill health and disability, with treatments often proving insufficient. Recent study has increasingly found a strong correlation between gut microbiome diversity and mood-related behaviors, including MDD. Depression can alter gut microbiota (GM) composition, while intentional modulation of the GM may conversely influence depressive symptoms. This phenomenon arises from dynamic bidirectional interactions between the gut and brain, although the exact pathways are not yet fully elucidated. Proposed pathways include, but are not limited to, neural circuits, the endocrine system, immune responses, and metabolic regulation. Clinical data have also shown that regulating the GM through probiotics and prebiotics has the potential to alleviate depressive symptoms. This review summarizes contemporary research on the composition and modulatory functions of GM in MDD, and explores the predictive potential of GM for depression as well as the therapeutic prospects of probiotics, aiming to provide insights and directions for future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.